Advisor to UCB in the divestment of its generics business Kremers Urban (2014 -2015)
Advisor to Ares in the merger between Greer and Stallergenes (2015)nFairness Opinion to Novartis for the sale of its animal health & OTC businesses in India to Eli Lilly and GSK (2014-2015)
Global coordinator in the IPO of Super Sonic Imagine (2014)
Advisor to Ampliter, Amplifon controlling holding, for its exchangeable bond (2013) – c.Eur140mnAdvisor to Neuca / Penta consortium for the acquisition of Mediq Polish pharma retail business (2013, pending)
Advisor to Biogaran (generic division of Servier) for the acquisition of Pharlab, Brazil (2012) – undisclosed amountnAdvisor to Air Liquide for the acquisition of Gasmedi (c.Eur300) (2012)
Advisor to Air Liquide for the acquisition and delisting of LVL Medical (c.Eur300m) (2012)
Advisor to Couckinvest for the delisting of Omega Pharma (2012) – Eur1.2bnnAdvisor to Carmat for its €25 Rights issue (2011)
Advisor to AES for the sale of its capital to bioMérieux (2011) c. Eur180mnAdvisor to Celesio for its€350m convertible bond (2011) nAdvisor to Sanofi-aventis for the offer of Genzyme (2011)- Eur20bn hostile takeover
Advisor to Amplifon for its accelerated book building (2010)
Advisor to Alfawassermann for the acquisition of Laboratoires Iprad (2010) – undisclosed amount
Advisor to Alapis (Greece) for its rights issue (2009) c. Eur500m